AI + Thermal Imaging

Diabetic Foot Ulcer Early Detection and Prevention

DiabSense pairs thermal and visual imaging with AI to help clinicians and high-risk patients detect hotspots, asymmetries, and other risk markers linked to ulcers and complications — non-invasively and fast.

Request early access See devices
Note: This is a pre-commercial product. Not for diagnostic use. Pilot programs forthcoming.

The need

Diabetic Ulceration

Diabetic foot ulcers are extremely expensive, life-threatning event in deep diabetic patients. Ulceration is hard to detect beforehand, and takes a long time to cure with high blood glucose levels and lower blood circulation, commonly found in Diabetic patients

Early Detection - What's Missing

  • Correct tools for daily feet scan for inflamation
  • Deep analysis of circulation issues at clinics
  • Constant remote access to high-risk patients at home

Solution

Full Feet Scan at Home

Daily feet scan at home to detect inflamation early and prevent ulceration

Feet Characterization at Clinic

Deep analysis of diabetic patient feet to detect blood circulation issues early on

Wound Characterization and Monitoring

Continuous monitoring and characterization of wound in order to keep track of wound progress and current condition

How DiabSense works overview

Products

FootScan Pro clinical scanner

FootScan Pro Clinic

Our clinical device for outpatient and wound-care settings. Designed for workflow speed, repeatability, and secure reporting.

  • Dual imaging (thermal + RGB), fixed geometry
  • Automated alignment & AI-assisted analysis
  • Report export & secure sharing

FootScan Home At-home

An easy-to-use home device to help high-risk patients track changes between visits and escalate when needed.

  • Guided capture with on-device checks
  • Trend views & clinician-shareable reports
  • Lightweight, compact design
FootScan Home device in hand

Team & Expertise

Kosala Jayasundara headshot

Kosala Jayasundara

Founding CEO

20+ years in product development and business management.

Thusitha Samarasekara headshot

Thusitha Samarasekara

CTO

16 years of expertise in electronic product development.

Tharini Thisakya headshot

Tharini Thisakya

Business Development Lead

5 years in business management and partnerships.

Gaweshika Liyadipita headshot

Gaweshika Liyadipita

Project Management

Engineering background; 3 years of medical product PM experience.

Ravini Samarakoon headshot

Ravini Samarakoon

Clinical Manager

Biomedical analysis and clinical program management.

Consultants & Medical Advisors

Professor Shervanithi headshot

Prof. Shervanithi

Lead Medical Officer

Esteemed vascular surgeon; professor at Leeds and UCL (UK).

Dr. Thushan headshot

Dr. Thushan

Medical Officer

Leads local clinical trials; Sri Lankan medical advisor.

ExcelTech OÜ logo

ExcelTech OÜ

Engineering Partner

Electronics, firmware, cloud, apps, testing, and certification.

Tehnopol logo

Tehnopol

Business Consultancy

Leading Startup Hub in Estonia.

Launch timeline

Concept and Business Analysis
2024 — completed
Early Prototyping
2025 Q1–Q2 — completed
Pre-Clinical Testing
2025 Q1–Q4 — on-going
Advanced Prototype & Comprehensive Pre-Clinical Validation
2025 Q3–Q4 — on-going
Full Product Development
2025 Q2 to 2026 Q2 — on-going
Clinical Trials
Target: 2026 Q3 to 2027 Q1
Product Certification and FDA Application / Approval
Target: 2026 Q3 to 2027 Q1
Pilot Launch (Sampling and Mini bulks)
Target: 2027 Q3 to 2028 Q2
Bulk Launch Start (Singapore + UAE)
Target: 2028 Q4
Continuous Expansion to Multiple Countries
Starting from 2029

What to expect

  • Transparent milestone updates for partners and clinics
  • Early-access program with feedback loops
  • Security & privacy by design in all releases
Want your clinic in the pilot? Contact us.

Investment Opportunity

We are offering investment opportunity for interested investors at ARR above 30%.

  • TAM: 45 Billion USD. SAM: 4 Billion USD. SOM: 220Million USD in 5 years
  • Annual Rate of Return for Investment: >30%
  • Income model: 80% long term subscription income, 20% point of sales income
  • Exit Plans:
    • Plan 1: Aquicition by a big MedTech brand in 2030 (Highly probable)
    • Plan 2: IPO by 2033 (2nd option)
Email us
TAM / SAM / SOM overview

Contact us

Use the form below or email [email protected]. No data is stored on this site; your email client will open to send your message.

Email directly